Inotiv, Inc. (NOTV) is a Medical - Diagnostics & Research company in the Healthcare sector, currently trading at $0.24. It has a SharesGrow Score of 37/100, indicating a weak investment profile with 2 out of 7 criteria passed.
Analyst consensus target is NOTV = $3 (+1149% upside).
Valuation: NOTV trades at a trailing Price-to-Earnings (P/E) of -0.1 (S&P 500 average ~25) with a forward Price/Earnings-to-Growth (PEG) of 0.01.
Financials: revenue is $513M, -1.7%/yr average growth. Net income is $69M (loss), growing at +34.1%/yr. Net profit margin is -13.4% (negative). Gross margin is 12.7% (-16 pp trend).
Balance sheet: total debt is $504M against $136M equity (Debt-to-Equity (D/E) ratio 3.7, leveraged). Current ratio is 0.35 (tight liquidity). Debt-to-assets is 65.3%. Total assets: $771M.
Analyst outlook: 2 / 3 analysts rate NOTV as buy (67%) — moderate consensus.
SharesGrow 7-Criteria breakdown: Value 100/100 (Pass), Growth 58/100 (Partial), Past 0/100 (Fail), Health 0/100 (Fail), Moat 15/100 (Fail), Future 73/100 (Pass), Income 10/100 (Fail).
